These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 22192663)

  • 1. Classification and clinical impact of restenosis after femoropopliteal stenting.
    Tosaka A; Soga Y; Iida O; Ishihara T; Hirano K; Suzuki K; Yokoi H; Nanto S; Nobuyoshi M
    J Am Coll Cardiol; 2012 Jan; 59(1):16-23. PubMed ID: 22192663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention.
    Armstrong EJ; Singh S; Singh GD; Yeo KK; Ludder S; Westin G; Anderson D; Dawson DL; Pevec WC; Laird JR
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1168-74. PubMed ID: 23630047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis.
    Armstrong EJ; Thiruvoipati T; Tanganyika K; Singh GD; Laird JR
    J Endovasc Ther; 2015 Aug; 22(4):506-13. PubMed ID: 26130385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center.
    Shammas NW; Shammas GA; Helou TJ; Voelliger CM; Mrad L; Jerin M
    Cardiovasc Revasc Med; 2012; 13(4):224-7. PubMed ID: 22575073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
    Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
    J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ; Oyama JK; Luu JT; Stinis CT
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.
    Shammas NW; Shammas GA; Banerjee S; Popma JJ; Mohammad A; Jerin M
    J Endovasc Ther; 2016 Apr; 23(2):339-46. PubMed ID: 26921281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries.
    Sabeti S; Mlekusch W; Amighi J; Minar E; Schillinger M
    J Endovasc Ther; 2005 Feb; 12(1):6-12. PubMed ID: 15683273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation.
    Nakazawa KR; Wengerter SP; Power JR; Lookstein RA; Tadros RO; Ting W; Faries PL; Vouyouka AG
    J Vasc Surg; 2017 Jul; 66(1):151-159. PubMed ID: 28259571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.